All In Biotech

Free tool

FAERS Monitor: Opzelura

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215309 or its brand name (Opzelura, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.

Reports

15,313

Serious

10,796

71% of reports

Hospitalization

4,226

Death reported

2,698

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,316
  • drug ineffective1,422
  • product use in unapproved indication859
  • death797
  • anaemia742
  • pyrexia618
  • pneumonia589
  • thrombocytopenia564
  • platelet count decreased536
  • pruritus517
  • haemoglobin decreased511
  • fatigue462
  • febrile neutropenia458
  • splenomegaly446
  • product availability issue434

Reports by year received

View as table
YearReports
201211
201314
201422
201553
2016104
2017209
2018299
2019336
2020530
20211,110
20221,775
20233,230
20242,774
20252,725
20262,121

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
splenomegalySignal44654.349.522,404
product availability issueSignal43426.724.310,505
febrile neutropeniaSignal4589.58.73,481
thrombocytopeniaSignal5647.06.42,872
platelet count decreasedSignal5366.96.42,718
haemoglobin decreasedSignal5116.96.32,554
anaemiaSignal7425.45.02,641
product use in unapproved indicationSignal8594.84.52,580
off label useSignal2,3163.63.54,612
pneumoniaSignal5892.52.3537
pyrexiaSignal6182.52.3540
pruritus5171.81.7204
drug ineffective1,4221.51.4237
death7971.31.248
fatigue4620.80.720

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.